The HARMONY Alliance uses big data technologies to improve the treatment of seven hematologic malignancies. These are cancers that affect the blood and lymphatic system. In recent decades, diagnosis and treatment of these diseases has substantially improved, but many remain incurable. Taken together, hematologic malignancies rank third after lung cancer and colorectal cancer in terms of age-adjusted mortality in Europe. In addition, they strongly contribute to loss of productivity.
The key outstanding questions in this field can only be answered by studying large numbers of patients. Therefore, the HARMONY Alliance will generate a harmonized European clinical data platform, assembling data from thousands of European patients. This will enable the HARMONY researchers to characterize the molecular landscape of the seven malignancies, understand their pathophysiology, and identify novel drug targets. In addition, it will allow us to reliably predict disease course and drug response for subgroups of patients. Ultimately, this should result in tools to rapidly select the most promising treatment strategy for a particular patient (i.e. personalized medicine). HARMONY aims to meet the needs of patients with hematologic malignancies by increasing treatment efficacy, decreasing adverse effects, prolonging survival, and increasing patients’ quality of life.
HARMONY focus: 7 HMs: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CALL), Multiple Myeloma (MM), Myelodysplastic Syndromes (MDS), Non-Hodgkins Lymphoma (NHL) and Pediatric Hematologic Malignancies. Learn more, click on the colored blocks below.